HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $20
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) but lowers the price target from $24 to $20.
August 04, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $24 to $20, HC Wainwright & Co. maintains a 'Buy' rating on Coherus BioSciences, indicating continued confidence in the company.
The lowered price target could potentially indicate a perceived decrease in the company's future performance. However, the maintained 'Buy' rating suggests that the analyst still sees potential in the company's stock, which could balance out any negative impact from the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100